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The Nef protein of primate immunodeficiency viruses
plays an important role in the pathogenesis of acquired
immunodeficiency syndrome (AIDS) [1,2]. The interaction
of Nef with the Nef-associated kinase (NAK) is one of the
most conserved properties of different human and simian
immunodeficiency virus (HIV and SIV) Nef alleles. The
role of NAK association is currently not known but it has
been implicated in enhanced viral infectivity in cell
culture and in disease progression in SIV-infected
macaques [3]. Previous studies have indicated that NAK
shares many features with the p21-activated kinases
(PAKs) [3], but the molecular identity of NAK has
remained unknown. We have generated specific antisera
against PAKs 1–3, and expressed these kinases
individually as epitope-tagged proteins. By using these
reagents in experiments involving partial proteolytic
mapping, and exploiting the unique ability of PAK2 to
serve as a caspase substrate, we have positively
identified NAK as PAK2. Interestingly, although ectopic
PAK2 overexpression efficiently replaced endogenous
PAK2 from the complex with Nef, the total Nef-associated
PAK2 activity was not increased, indicating the
abundance of another cellular factor(s) as the limiting
factor in Nef–PAK2 complex formation. Identification of
NAK as PAK2 should now facilitate elucidation of its role
as a mediator of the pathogenic effects of Nef.
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Results and discussion
Detailed studies of the role of NAK in mediating the
actions of Nef have been hampered by the failure to iden-
tify this kinase. Although PAK1 has been considered a
probable candidate [4], the prevailing hypothesis has
been that NAK represents a new member of the PAK
family [5,6]. PAKs are a subfamily of STE20 kinases and,
at present, there are four PAKs: PAK1 (αPAK or PAK65
in rat), PAK2 (hPAK65, rat γ-PAK, rabbit PAK-I), PAK3
(rat β-PAK) and PAK4. In contrast to the other PAKs,
PAK4 lacks an amino-terminal proline-rich region that
has been shown to target PAK1 to the adapter protein
Nck [7,8]. As NAK also has the ability to associate with
Nck [5], we ruled out PAK4 as a NAK candidate.
Serological characterisation of NAK
Previous studies have shown that autophosphorylated NAK
that has been radiolabelled in an in vitro kinase assay and
eluted from anti-Nef immunocomplexes can be re-
immunoprecipitated by antisera raised against peptides cor-
responding to the amino- and carboxy-terminal sequences
of PAK1 [4,9]. Notably, however, the amino and carboxyl
termini of PAK2 and PAK3 share extensive sequence
homology with PAK1. Although we could readily confirm
the ability of anti-PAK antibodies to re-immunoprecipitate
NAK (see later), we found that the amount of anti-PAK
reactive material in anti-Nef immunoprecipitates was too
low to be detected by western blot using the same antibod-
ies. Therefore, in our further serological studies on the
identity of NAK, we chose to use the sensitive in vitro
kinase assay/re-immunoprecipitation approach.
To produce more specific anti-PAK antibodies, we immu-
nised rabbits with PAK1, PAK2 and PAK3 peptides corre-
sponding to the few divergent regions in these proteins.
To test the specificity of our own as well as the commer-
cial anti-PAK antisera, we separately expressed PAK1, 2 or
3 as haemagglutinin (HA)-tagged proteins. These were
immunoprecipitated with anti-HA antiserum, eluted from
the immunocomplexes with the HA peptide, and subse-
quently subjected to re-immunoprecipitation using the
different anti-PAK antibodies (Figure 1, upper three
panels). In parallel experiments, we eluted NAK from
anti-Nef antibody immunocomplexes from Nef-trans-
fected cells, and compared the ability of the different anti-
PAK antisera to recognise NAK (Figure 1, bottom panel)
with their relative specificities in re-immunoprecipitation
of HA- tagged PAK 1, 2 and 3.
As shown in Figure 1, our studies confirmed that the
widely used amino- and carboxy-terminal anti-PAK1 antis-
era (P1N and P1C) were able to re-immunoprecipitate
NAK that was released from an anti-Nef 
immunoprecipitation. Nevertheless, from the parallel re-
immunoprecipitation of PAKs 1–3 it can be seen that P1N
and P1C, which efficiently precipitated PAK1 as expected,
were also able to precipitate PAK2. Among the commercial
antibodies, the only relatively specific antiserum was the
P2V antibody, raised against a region in the PAK2 amino
terminus. By contrast, the antisera we raised against pep-
tides corresponding to divergent regions of the PAKs were
remarkably specific (Figure 1, compare the signals of the
lanes PAK1-R1 and PAK2-R2 in the upper three panels).
The most notable finding using this set of antibodies was
that both the P2V antibody and our anti-PAK2-R2 anti-
body could precipitate both PAK2 and NAK and not PAK1
and PAK3. From these experiments, we concluded that
NAK is immunologically identical to PAK2. 
Characterisation of NAK by proteolytic digestion
To further substantiate this conclusion, we performed
limited in-gel digestions for the three PAKs and NAK
using two different proteases. As seen in Figure 2, PAK2
and NAK had very similar digestion patterns for both chy-
motrypsin and the endoproteinase Glu-C, whereas the
digestion patterns of PAKs 1 and 3 were clearly different
from NAK. Minor differences in the relative intensities of
fragments in the NAK and PAK2 digestions could well be
explained by small differences in the phosphorylation of
these proteins.
Although the PAKs are highly homologous proteins, only
PAK2 is known to be a substrate of caspase 3 (also known
as CPP32 or apopain), one of the downstream effector pro-
teases of the proteolytic cascades occurring during apopto-
sis [10]. Only PAK2 contains the consensus cleavage site
for DEVD-sensitive caspases located between Asp212 and
Gly213 in the linker region between the amino-terminal
regulatory and the carboxy-terminal kinase domain [11].
We have exploited this remarkable difference between
the PAKs to obtain further proof that NAK is indeed
PAK2. After immunoprecipitation and subsequent in vitro
kinase assay, the radiolabelled proteins were incubated
with caspase 3 for the indicated time periods. From this
experiment (Figure 2b), it can be clearly seen that the
only proteins that were cleaved by caspase 3 were PAK2
and NAK. As most (6 out of 7) of the potential PAK2 phos-
phorylation sites are located in the amino-terminal domain
of the protein [12], only this cleavage product was visible
in this experimental set-up. From the comparable chy-
motrypsin and Glu-C digestion patterns and the sensitiv-
ity of NAK to caspase 3 we conclude that, in 293T cells,
NAK is identical to PAK2
As it was formally possible that NAK represents different
PAKs in different cell types, we analysed NAK from Nef-
transfected HeLa and Jurkat cells. We found that the chy-
motrypsin pattern of NAK from 293T cells was identical to
the patterns from HeLa and Jurkat cells. Also, NAK from
these three different cell types was similarly sensitive to
caspase 3 digestion in vitro (see Supplementary material). 
Except for exploiting the ability of caspase 3 to specifically
cleave PAK2, our experimental approaches were not very
different from those used in previous studies, which did
not lead to the identification of NAK as PAK2 [4,6,9]. Nev-
ertheless, it is easy to see how crossreactivity of the anti-
PAK antibodies used for re-immunoprecipitation of NAK
from anti-Nef immunocomplexes, as well as the uncertain
identity of the kinases precipitated from cells with anti-
PAK reagents for comparison of their proteolytic patterns
with NAK, could have contributed to the inconclusive
results of these studies. In addition to serological character-
isation, previous studies aimed at identifying NAK used
dominant-negative forms of different PAKs. Because of the
extensive homology of the PAKs, however, such results are
equally prone to misinterpretation, as different dominant-
negative PAKs are expected to be cross-inhibitory.
Transfected PAK2 can substitute for endogenous NAK
Having identified NAK as PAK2, we were puzzled by our
initial findings indicating that overexpression of PAK2 did
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Figure 1
Re-immunoprecipitation of PAKs 1–3 and NAK using different
antibodies. Human embryonic kidney 293T cells were transfected with
HA-tagged PAK1, PAK2 or PAK3, or with Nef. All were cotransfected
with the dominant active version of Cdc42 (Cdc42V12).
Immunoprecipitation (IP) was performed using anti-HA antibody (for
PAKs 1–3) or with the 2F2 anti-Nef monoclonal antibody. After in vitro
kinase assay, the radiolabelled proteins were eluted with the HA
epitope peptide (for PAKs 1–3) or with the 2F2 epitope peptide (for
Nef). Eluted proteins were re-immunoprecipitated (re-IP) with the
different antibodies and run on SDS–polyacrylamide gels. The
commercial anti-PAK antibodies used are: P1N, raised against the
amino terminus of PAK1; P1C, raised against the carboxyl terminus of
PAK1; P2N, raised against the amino terminus of PAK2; P2V, raised
against a sequence at the amino terminus of PAK2; and P3N, raised
against the amino terminus of PAK3. Antibodies PAK1-R1, PAK2-R2
and PAK3-R3 were raised in rabbits against sequences that are
divergent in the different PAK proteins. 
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not increase the NAK signal. Indeed, when we repeated
these experiments by transfecting PAK2–HA along with
Nef, we did not see an increase in NAK signal compared
with transfection of Nef alone (Figure 3, uppermost
lanes). We did, however, observe a small upward shift in
the mobility of the NAK when HA-tagged PAK2 was
coexpressed, suggesting that the overexpressed
PAK2–HA, which has a slightly slower mobility because of
the tag, might be able to replace the endogenous PAK2 in
the complex with Nef. We addressed this by eluting the
NAK band from anti-Nef immunoprecipitates from cells
transfected with either only Nef or with Nef and
PAK2–HA. As a control, cells cotransfected with Nef and
PAK1–HA were used. The eluted NAK was then re-
immunoprecipitated with the PAK2-R2 antiserum or with
anti-HA antibody. NAK from cells transfected with Nef
alone could only be re-precipitated with the PAK2 anti-
serum but not with the anti-HA antibody, and therefore
represented endogenous PAK2. NAK from cells cotrans-
fected with PAK2 could be precipitated with both antis-
era, however, proving that overexpressed PAK2–HA could
replace the endogenous PAK2 in the Nef–NAK complex.
By contrast, PAK1–HA could not replace the endogenous
PAK2 as the NAK band from cells cotransfected with
PAK1–HA could only be precipitated with the PAK2 anti-
serum, but not with anti-HA antibody. Similar, high-level
expression of PAK1–HA and PAK2–HA in these experi-
ments was confirmed by western blot analysis (data not
shown). Thus, although overexpression of PAK2–HA did
not increase the NAK signal, it could replace the endoge-
nous PAK2 in the complex with Nef, suggesting that
another component(s) in the complex is limiting. 
PAKs have been implicated in many different functions
[13], such as cytoskeletal regulation, activation of the Jun
N-terminal kinase (JNK)/p38 mitogen-activated protein
(MAP) kinase signalling pathway and apoptotic signalling.
Many of these functions could be involved in regulation of
the replicative cycle of HIV, and thus represent potential
targets of Nef action. It is possible that Nef could modulate
the effects of PAK2 in mediating signalling from the cyto-
plasm into the nucleus and/or in inducing re-organisation of
the actin cytoskeleton, both of which could facilitate some
step(s) in the HIV life cycle, such as transcription, reverse
transcription, or budding. Our current observation that Nef
specifically interacts with PAK2, the only PAK family
member that is cleaved and activated by pro-apoptotic cas-
pases, adds even more possibilities to this list. For example,
the Nef–PAK2 interaction might modulate the sensitivity
of HIV-infected cells to apoptosis or, alternatively, induce
some apoptosis-like changes in the cellular physiology,
which could favour HIV replication without causing an
immediate destruction of the infected cells. 
Identification of NAK as PAK2 will now enable more
sophisticated experiments to address these and other out-
standing questions regarding the role of PAK2 as a media-
tor of the pathogenic effects of Nef, as well as to examine
its value as a potential therapeutic target in AIDS.
Materials and methods
Plasmids and transfections
Transfections to 293T human embryonic kidney fibroblast-derived cells
were done using the lipofectamine transfection agent (Gibco BRL)
according to the manufacturer’s instructions. Plasmid pEBB-PAK1HA [8]
was kindly provided by B. Mayer (Harvard); pEBB-PAK2HA was gener-
ated by replacing the BamH1–Kpn1 fragment of pEBB-PAK1HA contain-
ing the PAK1 coding sequence by a PCR product containing the PAK2
sequence derived from human cDNA. Similarly, pEBB-PAK3HA was
made by cloning a rat PAK3-containing fragment generated by PCR from
pXJ40-HA-PAKβ (kindly provided by E. Manser). The NL4-3 Nef allele
R71 [14] was cloned into the pEBB expression vector, without the HA
epitope tag. B. Mayer kindly provided pEBG-cdc42V12, which expresses
a fusion of glutathione-S-transferase (GST) with dominant-active Cdc42.
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Figure 2
Proteolytic comparison of NAK with PAKs
1–3. Cells (293T) were transfected with HA-
tagged PAK1, PAK2, PAK3, or Nef. All were
cotransfected with Cdc42V12.
Immunoprecipitations were performed with
anti-HA antibody (for PAK-transfected cells)
or with sheep anti-Nef antibody (for
Nef-transfected cells). (a) After an in vitro
kinase assay the radiolabeled PAK/NAK
proteins were excised from a preparative gel
and subjected to a subsequent in-gel
digestion electrophoresis with chymotrypsin
and Glu-C. The open and filled arrowheads
indicate the corresponding proteolytic
fragments in the PAK2 and NAK lanes in this
audiograph. (b) After the in vitro kinase assay,
these reaction products were subjected to
caspase 3 digestion for the indicated time
periods and analysed by electrophoresis.
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Antibodies
The Anti-Nef antibodies used were a polyclonal sheep serum raised
against GST–Nef (M. Harris) and a monoclonal antibody (2F2 [15],
kindly provided by Vladimir Ovod, IMT, Tampere) that was raised against
a peptide (amino acids 151–170) of the HIVnef BRU isolate. Anti-PAK
antibodies P1N, P1C, P2N, PAK2V and P3N were purchased from
Santa Cruz Biotechnology. Antibodies against PAK1-R1, PAK2-R2 and
PAK3-R3 were raised in rabbits against cocktails of selected sequences
that are divergent in the different PAK proteins. Peptides were made as
multiple-antigen peptides, (peptide)8–K4–K2–K–A. Anti-HA antibodies
were derived from BAbCO.
Re-immunoprecipitation
After immunoprecipitations and subsequent in vitro kinase assays (per-
formed as described before [5]), beads were washed with PBS and
incubated with 1 mg/ml of the peptide corresponding to the epitope
used for immunoprecipitation. Eluted proteins were subjected to beads
pre-bound with antibodies and incubated overnight at 4°C. Beads were
washed with PBS and boiled in SDS sample buffer. Proteins were run
on SDS–PAGE and visualised by autoradiography.
Limited in-gel protease digestion
Radiolabelled bands were cut from SDS–polyacrylamide gels and
allowed to rehydrate in 1:10 diluted SDS–PAGE sample buffer. Gel
pieces were transferred to the wells of a 13% SDS–polyacrylamide gel
and minced with a needle. Chymotrypsin (500 ng per well, Sigma) or
endoproteinase Glu-C from Staphylococcus aureus V8 (2 µg per well,
Sigma) were added in 1:10 sample buffer. After stacking, electrophore-
ses was stopped for 30 min and then continued overnight. After elec-
trophoreses, the gel was dried and exposed to Biomax MR film (Kodak).
In vitro caspase 3 digestion
After the in vitro kinase assay, as described above, beads were
washed with PBS, equilibrated with digestion buffer (DB, 25 mM
HEPES pH 7.4, 1 mM DTT), and incubated with 40 ng caspase 3 in
DB (Calbiochem) at 37°C for the indicated time points. The reactions
were stopped by the addition of SDS–PAGE sample buffer. 
Supplementary material
Supplementary material including additional methodological detail and
a figure demonstrating that NAK from 293T cells is identical to NAK
from Jurkat T cells and HeLa cells is available at http://current-
biology.com/supmat/supmatin.htm 
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Figure 3
Cotransfection of Nef and PAK2. Cells (293T) were transfected with the
plasmids encoding the indicated proteins. All cells were also transfected
with the Cdc42V12 plasmid. Cell extracts were immunoprecipitated with
the 2F2 anti-Nef antibody and subjected to in vitro kinase assay. Part of
each sample was subjected to electrophoresis (total); the rest was eluted
with the 2F2 epitope peptide. Part of the eluate was analysed directly on
gel (eluate); the rest was split into two fractions, one of which was re-
immunoprecipitated with the PAK2-R2 antibody, the other with the anti-
HA antibody before they were subjected to electrophoresis.
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Supplementary materials and methods
Generation of cell lines containing stably transfected inducible Nef
constructs, HeLa (BH10) and Jurkat (51–31), and the control Jurkat
line (MT-11) have been described [S1]. The low basal level of Nef
expression from these regulatable but leaky constructs was sufficient
for optimal NAK signal in these cell lines. 
Supplementary reference
S1. Cooke SJ, Coates K, Barton CH, Biggs TE, Barrett SJ, Cochrane A, et
al.: Regulated expression vectors demonstrate cell-type-specific
sensitivity to human immunodeficiency virus type 1 Nef-induced
cytostasis. J Gen Virol 1997, 78:381-392.
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Figure S1
In-gel digestion and caspase 3 sensitivity of
NAK from different cell types. Extracts of
293T, HeLa and Jurkat cells expressing Nef
were immunoprecipitated with the sheep
anti-Nef antiserum. (a) In vitro kinase assays
were subjected to electrophoresis and the
radiolabelled protein bands (arrowheads)
were cut out and subjected to in-gel digestion
with chymotrypsin. (b) After in vitro kinase
assay, caspase 3 digestion was performed for
the indicated time periods.
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